Latest Inflammation News

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.